Accelerating research

and development of

new antibiotics and

alternatives

The Netherlands Antibiotic Development Platform

The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.

NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.

Stay informed on NADP and subscribe to our Update.

NADP Vouchers

An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.

These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.

Latest News

GARDP present REVIVE: Advancing Antimicrobial R&D

The GARDP (Global Antibiotic Research & Development Partnerships) has three upcoming webinars. The organization has organized these live seminars to discusscurrent challenges in antibiotic research.

Read More...

WHO calls for new ways to tackle AMR

The World Health Organization has released a report on antimicrobial-resistant (AMR) bacterial pathogens. The analysis points to the need of accelerating vaccine development and maximizing current vaccines related to AMR.

Read More...

Investigation next-generation antibiotics continues with ERC grant Nathaniel Martin

Nathaniel Martin has received the Proof of Concept (PoC) grant. The European Research Council (ERC) awarded Martin this grant to continue his research on reducing the toxicity of the antibiotic polymyxin: A potent medicine, but with severe side effects. He receives €150.000.

Read More...

NADP Partners

Supported by

NADP Partners

Supported by